Notice on access to Leqembi (lecanemab)
The US Food and Drug Administration (FDA) has recently approved amyloid-targeting drug lecanemab (Leqembi) for the treatment of early stage Alzheimer’s disease. This is a historic development for those affected by this debilitating disease and their loved ones.
See our full blog post on this announcement here.
If you or a loved one has been diagnosed with early onset Alzheimer’s disease and are interested in exploring treatment options like Leqembi, we encourage you to contact a memory specialist at Isaac Health. Our team can help you understand the eligibility requirements for the clinical study and assist with the enrollment process if you qualify.
Isaac Health is hoping to provide access to the drug for qualifying self-pay patients from end of January and through funded clinical trials later.